Akkermansia muciniphila and Akkermansia muciniphila for Insulin sensitivity / metabolic markers
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Compound or practice
Akkermansia muciniphila
A next-generation gut bacterium linked to metabolic health — one promising human trial, a lot still unknown.
Grade C1 graded outcomerevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Evidence brief
Akkermansia muciniphila for Insulin sensitivity / metabolic markers
Evidence grade C — One key trial
Grade C1 graded outcomerevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
| Outcome | Akkermansia muciniphila | Akkermansia muciniphila for Insulin sensitivity / metabolic markers |
|---|---|---|
| Insulin sensitivity / metabolic markers | Evidence grade CSmall effectlowOne key trial | Evidence grade CSmall effectlowOne key trial |
Graded only in Akkermansia muciniphila
None — every outcome it grades is graded in both.
Graded only in Akkermansia muciniphila for Insulin sensitivity / metabolic markers
None — every outcome it grades is graded in both.
What each entry says about the other
- Akkermansia muciniphila for Insulin sensitivity / metabolic markers’s entry · Goes with: Read the full Akkermansia muciniphila monograph
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.